Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarloxotinib in EGFR-Mutant T790M-Negative Advanced NSCLC
NCT02454842Phase 2Terminated
- Sponsor
- Rain Oncology Inc.
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tarloxotinib in non-small cell lung cancer (NSCLC), sponsored by Rain Oncology Inc. Primary endpoint: Number of participants with response rate as evaluated by RECIST criteria at 12 months. Started Jun 2015; status: terminated.
02
Drugs
tarloxotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02454842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454842.